Results 191 to 200 of about 25,686,348 (370)
Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale
ABSTRACT The placebo response in clinical trials in ataxias complicates outcome interpretation and potentially obscures genuine treatment effects. We analyzed placebo group data from past trials in Friedreich Ataxia and observed notable responses in appendicular items, in contrast to minimal changes in axial function, as measured by respective ...
Christian Rummey +2 more
wiley +1 more source
Golay [[11,1,5]]₃ Protocol — 11-Qutrit Sonification & Spectral Analysis
Slade, Trent
openalex +1 more source
EEG ELECTRODE LOCALIZATION FOR READING-WRITING NEUROPATHWAY: SPECTRAL ANALYSIS APPROACH
N. B. Mohamad +3 more
openalex +1 more source
ABSTRACT Mutations in myelin regulatory factor (MYRF) are linked to demyelinating disorders. We report a 38‐year‐old male who developed acute symmetric leukoencephalopathy mimicking a stroke following an influenza A virus infection. While clinical symptoms markedly improved with corticosteroids, MRI revealed persistent white matter lesions, contrasting
Jinghan Hu +5 more
wiley +1 more source
Sensor-Based Evaluation of Purslane-Enriched Biscuits Using Multivariate Feature Selection and Spectral Analysis. [PDF]
Baycheva S +5 more
europepmc +1 more source
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Outdoor Microphone Range Tests and Spectral Analysis of UAV Acoustic Signatures for Array Development. [PDF]
Jekateryńczuk G, Piotrowski Z.
europepmc +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

